[1]杨柳, 王殊. 晚期三阴性乳腺癌的治疗进展[J]. 中国普通外科杂志, 2019, 28(11):1342-1346. doi:10.7659/j.issn.1005-6947.2019.11.004
[2]Lin NU, Vanderplas A, Hughes ME, et al.Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. Cancer, 2012 Nov;118(22):5463-72. DOI: 10.1002/cncr.27581.
[3]https://mp.weixin.qq.com/s/Dukg6V6_tBzLIyJCyLzFtw
[4]https://www./what-is-brca
[5]Gonzalez-Angulo AM, Timms KM, Liu S, et al. Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer.Clin Cancer Res. 2011;17(5):1082. Epub 2011 Jan 13.
[6]郑宇静, 左彤彤, 封宇飞. 靶向DNA损伤反应途径:PARP抑制剂抗肿瘤治疗研究进展[J]. 中国药理学通报, 2018, 34(2): 157-160.
[7]https://www./news-events/press-announcements/fda-approves-first-treatment-breast-cancer-certain-inherited-genetic-mutation
[8]Robson M, Im SA, Senkus E, et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N Engl J Med 2017; 377:523.
[9]Schmid P, Chui SY, Emens LA. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. Reply[J]. N Engl J Med, 2019, 380(10):987–988. doi: 10.1056/NEJMc1900150.
[10]Schmid P, Adams S, Rugo HS, et al. IMpassion130: updated overall survival (OS) from a global, randomized, double-blind, placebo-controlled, Phase III study of atezolizumab (atezo) + nab-paclitaxel (nP) in previously untreated locally advanced or metastatic triple-negative breast cancer (mTNBC). J Clin Oncol 2019; 37S: ASCO #1003.
[11]https://investors./news/press-release-details/2019/Mercks-KEYTRUDA-pembrolizumab-Plus-Chemotherapy-Showed-Statistically-Significant-Increase-in-Pathological-Complete-Response-Versus-Chemotherapy-as-Neoadjuvant-Therapy-in-Early-Stage-Triple-Negative-Breast-Cancer-TNBC/default.aspx
[12]https://investors./news/press-release-details/2020/Mercks-KEYTRUDA-pembrolizumab-in-Combination-with-Chemotherapy-Met-Primary-Endpoint-of-Progression-Free-Survival-PFS-as-First-Line-Treatment-for-Metastatic-Triple-Negative-Breast-Cancer-mTNBC/default.aspx